NDA 217785 · Madrigal
Rezdiffra
Resmetirom · Oral · Thyroid Hormone Receptor beta Agonist
NovelBreakthrough therapyAccelerated approvalPriority reviewCDER novel approval, Mar 14, 2024: To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Mar 14, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
4 Phase 3, 7 recruiting
FAERS reports
2,298
834 serious, 125 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 29, 2026.
REZDIFFRA ® is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Limitations of Use Avoid use of REZDIFFRA in patients with decompensated cirrhosis [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] . REZDIFFRA ® is a thyroid hormone receptor-beta (THR-beta) agonist indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1) Limitations of Use Avoid use of REZDIFFRA in patients with decompensated cirrhosis. (1)
Therapeutic areas: Infectious disease and vaccines · Gastroenterology and liver · Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 14, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
3 products under this application
- REZDIFFRA · RESMETIROM 60MG · TABLET, ORAL · Prescription
- REZDIFFRA · RESMETIROM 80MG · TABLET, ORAL · Prescription
- REZDIFFRA · RESMETIROM 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Resmetirom" as an intervention, any sponsor and status, largest first.
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisPivotal-lookingActive, not recruiting
Madrigal Pharmaceuticals, Inc.Industry
NCT03900429 · 1,759 participants · Start Mar 28, 2019 · Primary completion Jan 2028
Drug: MGL-3196; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 247 sites in all
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsPivotal-lookingCompleted
Madrigal Pharmaceuticals, Inc.Industry
NCT04197479 · 1,343 participants · Start Dec 16, 2019 · Primary completion Jan 6, 2023
Drug: Placebo; Resmetirom · For: Non-Alcoholic Fatty Liver Disease
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 77 sites in all
- A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)Pivotal-lookingActive, not recruiting
Madrigal Pharmaceuticals, Inc.Industry
NCT05500222 · 845 participants (planned) · Start Aug 26, 2022 · Primary completion Dec 2026
Drug: Resmetirom; Placebo · For: NASH; Cirrhosis, Liver
Sites: Birmingham, Alabama; Chandler, Arizona; Peoria, Arizona · 141 sites in all
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)Pivotal-lookingActive, not recruiting
Madrigal Pharmaceuticals, Inc.Industry
NCT04951219 · 810 participants · Start Jul 9, 2021 · Primary completion Mar 2027
Drug: Resmetirom · For: Non-Alcoholic Fatty Liver Disease
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 76 sites in all
Nabiqasim Industries (Pvt) LtdIndustry
NCT07249788 · 165 participants (planned) · Start Oct 17, 2025 · Primary completion Oct 16, 2026
Drug: Resmetirom · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Sites: Rawalpindi, Pakistan
Madrigal Pharmaceuticals, Inc.Industry
NCT07848191 · 150 participants (planned) · Start Oct 7, 2026 · Primary completion Nov 2027
Drug: Rezdiffra; Resmetirom and 2 more · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Sites: Chandler, Arizona; North Little Rock, Arkansas; Coronado, California · 16 sites in all
- Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)Pivotal-lookingCompleted
Madrigal Pharmaceuticals, Inc.Industry
NCT02912260 · 125 participants · Start Oct 18, 2016 · Primary completion Oct 25, 2017
Drug: MGL-3196; Placebo · For: Non-alcoholic Steatohepatitis
Sites: Dothan, Alabama; Tucson, Arizona; Coronado, California · 26 sites in all
- Nutrition Intervention Combined With Resmetirom for MASHPivotal-lookingNot yet recruiting
City University of New YorkAcademic, hospital or other
NCT07680478 · 120 participants (planned) · Start Oct 1, 2026 · Primary completion Feb 28, 2028
Drug: Resmetirom therapy · For: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea368
- nausea320
- pruritus301
- hepatic cirrhosis175
- fatigue169
- alanine aminotransferase increased161
- aspartate aminotransferase increased149
- abdominal pain upper138
- weight decreased131
- dizziness125
- vomiting117
- abdominal pain103
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 285 |
| 2025 | 929 |
| 2026 | 1,081 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rezdiffra (Resmetirom)
2024 spending
$69.1M
Beneficiaries
4,626
14,964 claims
Per beneficiary
$14,939
$131.97 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $69,106,677 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
Souza M, Al-Sharif L, Antunes VLJ, et al. · Hepatology 2025 · Systematic Review, Comparative Study
- Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.
Harrison SA, Taub R, Neff GW, et al. · Nat Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA, Bashir MR, Guy CD, et al. · Lancet 2019 · Clinical Trial, Phase II, Multicenter Study
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
Harrison SA, Browne SK, Suschak JJ, et al. · J Hepatol 2025 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.
Suvarna R, Shetty S, Pappachan JM · Sci Rep 2024 · Systematic Review, Meta-Analysis
Sponsor: Madrigal
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.